Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H25ClN2O |
| Molecular Weight | 344.878 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN1C=CC(N2CCC(CC2)C3=CC=CC=C3)=C(Cl)C1=O
InChI
InChIKey=HYOGJHCDLQSAHX-UHFFFAOYSA-N
InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
| Molecular Formula | C20H25ClN2O |
| Molecular Weight | 344.878 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:26:35 UTC 2023
by
admin
on
Sat Dec 16 10:26:35 UTC 2023
|
| Record UNII |
612BYT76F3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID601032323
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | |||
|
JNJ-40411813
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | Official Title: A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults With Major Depressive Disorder With Anxiety SymptomsPurpose: The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an antidepressant. | ||
|
25195461
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | |||
|
300000046596
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | |||
|
612BYT76F3
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | |||
|
ADX-71149
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | ADX-71149, also known as JNJ-4041183 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu2 receptor. It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms), but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. As of 2015, ADX-71149 is in phase II clinical trials for schizophrenia. | ||
|
DB12059
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY | |||
|
1127498-03-6
Created by
admin on Sat Dec 16 10:26:35 UTC 2023 , Edited by admin on Sat Dec 16 10:26:35 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->MODULATOR |
The pharmacokinetics and effects of JNJ-40411813 on cognition and subjective awareness were evaluated. Plasma JNJ-40411813 exposure was dose-dependent, t max ranged from 3-4 h and t 1/2 19.4-34.2 h across the dose levels. JNJ-40411813 significantly (p=0.02) reduced continuity of attention score (150 mg dose) and ameliorated smoking withdrawal-induced changes in power of attention and quality of episodic memory versus placebo. A modest reduction in alertness was observed at 150-225 mg doses, JNJ-40411813 (500 mg) reduced S(+) ketamine-induced negative symptoms by approximately 43% and 30% in cohorts 1 and 3, respectively. JNJ-40411813 was generally well-tolerated.
ALLOSTERIC ACTIVATOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Addex Pharmaceuticals; Developer: Janssen Pharmaceuticals; Class: Antidepressant, Antipsychotic, Anxiolytic, Small molecule; Mechanism of Action: Metabotropic glutamate receptor 2 modulators; Highest Development Phases: Phase II for Major depressive disorder, Schizophrenia; Phase I for Psychiatric disorders; Most Recent Events: 22 Apr 2016 Chemical structure information added, 29 Jul 2015 Phase-II development is ongoing as adjunctive therapy for schizophrenia and for anxiety in major depressive disorder, 01 Nov 2013 Janssen completes a phase II trial in Major Depressive Disorder (adjunctive treatment in patients with anxiety symptoms) in Bulgaria, Hungary, Moldova, Romania, Russia and Ukraine (NCT01582815)
|
